994 results on '"Prostatic tumor"'
Search Results
102. SV 40-transformed prostatic carcinoma in the hamster: Effect of hormonal manipulation on the growth rate.
103. A magic drug target: Androgen receptor.
104. Invited Speakers.
105. Abstracts.
106. Population pharmacokinetic–pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin.
107. Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain.
108. Association of anti‐inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
109. Androgen receptor expression reduces stemness characteristics of prostate cancer cells (PC3) by repression of CD44 and SOX2.
110. Therapeutic potency of Wnt signaling antagonists in the pathogenesis of prostate cancer, current status and perspectives.
111. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient‐derived xenograft (PDX) models.
112. Development of an orthotopic canine prostate cancer model expressing human GRPr.
113. Interleukin‐6 induced overexpression of valosin‐containing protein (VCP)/p97 is associated with androgen‐independent prostate cancer (AIPC) progression.
114. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
115. TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration‐Resistant Prostate Cancer.
116. Prostate tumors downregulate microseminoprotein‐beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness.
117. Capillarisin blocks prostate‐specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
118. Rictor regulates the vasculogenic mimicry of melanoma via the AKT- MMP-2/9 pathway.
119. Identification of a Potent Phosphoinositide 3-Kinase Pan Inhibitor Displaying a Strategic Carboxylic Acid Group and Development of Its Prodrugs.
120. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
121. Body mass index and prognosis in patients with head and neck cancer.
122. Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study.
123. Simultaneous automatic segmentation of multiple needles using 3D ultrasound for high-dose-rate prostate brachytherapy.
124. Knockout of 4.1B triggers malignant transformation in SV40T-immortalized mouse embryo fibroblast cells.
125. Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy.
126. Urethral Stenting.
127. Gestational and lactational exposition to Di- N-butyl-phthalate (DBP) increases inflammation and preneoplastic lesions in prostate of wistar rats after carcinogenic N-methyl- N-nitrosourea (MNU) plus testosterone protocol.
128. Combining lymphovascular invasion with reactive stromal grade predicts prostate cancer mortality.
129. Late prostatic metastasis of an uveal melanoma in a miniature Schnauzer dog.
130. Abstracts.
131. Multiparametric magnetic resonance imaging: Current role in prostate cancer management.
132. Analysis of caveolin-1 and phosphoinositol-3 kinase expression in primary uveal melanomas.
133. Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.
134. The Flame-Retardant Tris(1,3-dichloro-2-propyl) Phosphate Represses Androgen Signaling in Human Prostate Cancer Cell Lines.
135. Mutations and deletions of PRC2 in prostate cancer.
136. Systems Pharmacology Modeling of Prostate-Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down-Regulator.
137. Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study.
138. Real Time Metastatic Route Tracking of Orthotopic PC-3-GFP Human Prostate Cancer Using Intravital Imaging.
139. Histopathological features of intra-ductal carcinoma of prostatic and high grade prostatic intraepithelialneoplasia and correlation with PTEN and P63.
140. Evaluation of apparent diffusion coefficient and MR volumetry as independent associative factors for extra-prostatic extension (EPE) in prostatic carcinoma.
141. Cell line modeling to study biomarker panel in prostate cancer.
142. The Relationship Between Perineural Invasion, Tumor Grade, Reactive Stroma, and Prostate Cancer-Specific Mortality: A Clinicopathologic Study on a Population-Based Cohort.
143. Index Lesion Characterization by 11C-Choline PET/CT and Apparent Diffusion Coefficient Parameters at 3 Tesla MRI in Primary Prostate Carcinoma.
144. Targeting tumor suppressor genes for cancer therapy.
145. Targeting the relaxin hormonal pathway in prostate cancer.
146. Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.
147. Apparent diffusion coefficient ratio correlates significantly with prostate cancer gleason score at final pathology.
148. Intraepithelial lymphocytes in relation to NIH category IV prostatitis in autopsy prostate.
149. Marine Bioactive Compounds and Their Health Benefits: A Review.
150. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.